Literature DB >> 33158567

Primary cardiac lymphoma.

Kanhua Yin1, Hilliard Brydges2, Kyle W Lawrence2, Yaguang Wei3, Karl J Karlson2, David B McAneny4, Niloo M Edwards2, Michael J Reardon5, Nikola Dobrilovic6.   

Abstract

OBJECTIVE: This study aimed to understand the population-level treatment modalities and to evaluate the survival benefits of surgical resection in primary cardiac lymphoma.
METHODS: We queried the Surveillance, Epidemiology, and End Results Program database, which covers 35% of the US population. Patients with a histologic diagnosis of primary cardiac lymphoma from 1973 to 2015 were included. Multivariable accelerated failure time regression was performed to evaluate the associations between clinical factors and overall survival.
RESULTS: A total of 184 patients were identified. The median age was 68 years, 80% were White, and 46% were women. Diffuse large B-cell lymphoma (80%) was the most common histology, and the majority (65%) was low-stage lymphoma (Ann Arbor stage I or II). Median survival was 2.2 years. Seventy-three percent of patients received chemotherapy. Only 10% of patients received local resection or debulking. Multivariable analysis demonstrated that local resection or debulking was not independently associated with overall survival (adjusted hazard ratio, 0.67; 95% confidence interval, 0.30-1.48; P = .32). Instead, chemotherapy (adjusted hazard ratio, 0.4; 95% confidence interval, 0.23-0.69; P < .001) was independently associated with improved survival, whereas increasing age (adjusted hazard ratio of 5-year increment, 1.13; 95% confidence interval, 1.04-1.22; P <.001) and advanced stage (adjusted hazard ratio, 2.18; 95% confidence interval, 1.33-3.56; P < .001) were independently associated with worse survival.
CONCLUSIONS: Surgical resection was not independently associated with survival in patients with primary cardiac lymphoma. Chemotherapy was the predominant treatment option and associated with improved survival, whereas increasing age and advanced stage were independently associated with worse outcomes.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SEER; primary cardiac lymphoma; surgical resection; survival; treatment modality

Mesh:

Year:  2020        PMID: 33158567     DOI: 10.1016/j.jtcvs.2020.09.102

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   6.439


  4 in total

1.  Electrical storm due to Epstein-Barr virus-induced lymphoma of a transplanted heart: a case report.

Authors:  Etienne Charbonneau; Vincent Galand; Erwan Flécher
Journal:  Eur Heart J Case Rep       Date:  2022-06-13

2.  Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors.

Authors:  Elisa Lucchini; Marco Merlo; Mario Ballerini; Aldostefano Porcari; Gianfranco Sinagra; Lorenzo Pagnan; Marco Rensi; Andrea Romano; Rossana Bussani; Laura Ballotta; Francesco Zaja
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

3.  Commentary: Trim the fat.

Authors:  Thomas E MacGillivray; Michael J Reardon
Journal:  JTCVS Tech       Date:  2021-11-11

4.  Diagnosis of rapidly progressed primary cardiac lymphoma in liver transplant recipient: A case report.

Authors:  Jianghua Li; Qiyun Liu; Quanzhou Peng; Shaohong Dong
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.